Symposium on Oligometastatic
Esophagogastric Cancer
We are pleased to invite you to the symposium on oligometastatic esophagogastric cancer, which will take place on October 24th at the UMC Utrecht. This symposium offers an excellent opportunity for medical professionals to discuss and exchange knowledge on the latest developments and treatments in the field of oligometastases.
Recent evidence suggests that improved outcomes can be achieved when treating oligometastatic disease with a radical approach. We believe the time is ripe for collaboration to discover the best treatment strategies tailored to individual patients. This symposium will feature state-of-the-art strategies and near-future prospects in personalizing treatment for oligometastatic esophagogastric cancer, with top-level international experts from across Europe sharing their insights.
At the end of the symposium, we will celebrate the PhD defense of Tiuri Kroese on his thesis entitled
“Oligometastatic Esophagogastric Cancer.
Program
| 08:30 – 09:00 | Registration |
| Morning Chair Richard van Hillegersberg and Peter van Rossum | |
| 09:00 – 09:10 | Welcome – Richard van Hillegersberg |
| Local treatment for oligometastatic esophagogastric cancer | |
| 09:10 – 09:30 | Recommendations from the OMEC Project – Tiuri Kroese |
| 09:30 – 09:50 | MR-guided radiotherapy for oligometastatic disease – Martijn Intven |
| 09:50 – 10:10 | SBRT for rare oligometastatic cancers: the phase III OligoRARE trial – Matthias Guckenberger |
| 10:10 – 10:30 | Break |
| Hot topics in metastatic esophagogastric cancer | |
| 10:30 – 10:50 | Neck lymph node metastases: the phase II NODE trial – Richard van Hillegersberg |
| 10:50 – 11:10 | Peritoneal metastases: the phase III PERISCOPE trial – Johanna van Sandick |
| 11:10 – 11:30 | Oligometastases in the brain. Less is more? – Joost Verhoeff |
| 11:30 – 12:30 | Lunch |
| Afternoon Chair: Hanneke van Laarhoven and Jelle Ruurda | |
| Selecting patients for local treatment for oligometastatic esophagogastric cancer | |
| 12:30 – 12:50 | Determining minimal residual disease – Peter van Rossum |
| 12:50 – 13:10 | Targeted therapy and biomarkers for oligometastatic disease – Markus Moehler |
| 13:10 – 13:30 | Immunotherapy for oligometastatic disease and the OMEC-5 trial – Hanneke van Laarhoven |
| 13:30 – 13:50 | Break |
| Treatment of oligometastastic disease in esophagogastric cancer, current status from the: | |
| 13:50 – 14:10 | Dutch Upper Gastrointestinal Cancer Audit and Cancer Group (DUCA/ DUCG) – Bas Wijnhoven |
| 14:10 – 14:30 | Netherlands Cancer Registry (IKNL) – Rob Verhoeven |
| Closure of symposium and invitation for the PhD defense | |
| 16:15 – 17:15 | PhD defense Tiuri Kroese Academiegebouw, University Utrecht |